active
ACTIVE SINCE: 2022

CancerPath to Care

Directed by The Max Foundation with support from Novartis through drug donations and funding, CancerPath to Care™ connects people living with breast cancer and rare cancers, like chronic myeloid leukemia, with effective treatments, professional medical capabilities, trained physicians and hands-on support.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Global NGOs 1
Objectives
  • Provide access to care to people living with breast and rare cancers, like chronic myeloid leukemia (CML), in low- and middle-income countries (LMICs).
  • Accelerate health equity for cancer patients globally.

What are the health needs and challenges?

There is a lack of access to and reimbursement for cancer treatment in low- and middle-income countries (LMICs). Breast cancer is the leading cause of death for women worldwide and patients in low-resource settings face delayed diagnosis and poor access to treatment and care.

Partnership activities and how they address needs and challenges

Since 2002, The Max Foundation and Novartis have helped more than 90,000 patients in LMICs access treatment for chronic myeloid leukemia (CML) and other rare cancers through several programs.

The Glivec International Patient Assistance Program (GIPAP) was developed in 2002 to ensure patients with CML or GIST (gastrointestinal stromal tumor), two rare cancers, receive treatment. This direct-to-patient access program has provided treatment to approximately
75,000 people since its inception.

In 2017, Novartis announced the transition of this partnership to a new program called CMLPath to Care™, which aimed to support continued access to treatment at no cost for the nearly 34,000 previously registered patients in GIPAP with CML, GIST and other rare cancers. CMLPath to Care™ provided Glivec at no cost to patients who would not otherwise have access to treatment.

From April 2022, Novartis has launched CancerPath to CareTM, an extension of the CMLPath to CareTM program. This is a unique global initiative that connects people living with breast cancer and rare cancers, like CML, with effective treatments, professional medical capabilities, trained physicians and hands-on support. The initiative is directed by The Max Foundation with support from Novartis through drug donations and funding.

The collaboration aims to provide access to care to 36,000 people living with breast and rare cancers, like CML, in over 70 low- and middle-income countries by 2025. Eligible patients will have access to Novartis treatments for breast cancer (Kisqali® and Femara®), as well as those in our CML portfolio: Glivec®, Tasigna® and our novel therapy Scemblix®.

Early engagement with local healthcare institutions, treating physicians and departments of health are essential to the success of a program of this size and ambition. Equally important is clarity on the roles and responsibilities of all parties involved along with standard operating procedures to standardize processes across many disparate countries. Education on the program for physicians, governments, patients, distributors and others involved is also crucial.

The impact of the program is especially significant where local health institutions and civil organizations work together to improve facilities and educate patients and their families, thereby providing resources to offer integrated patient care.

Quote
“Novartis has once again demonstrated true leadership by stepping forward to join us in our mission to ensure that geography does not dictate one’s destiny. Through this unique collaboration, we have proven it is possible to erase the gap in patient outcomes in low- and middle-income countries, and we believe we can now do that for breast cancer.”
Pat Garcia-Gonzalez
CEO, The Max Foundation
Results and milestones

Since 2002, The Max Foundation and Novartis have helped more than 90,000 patients in LMICs access treatment for CML and other rare cancers through several programs.

The CancerPath to Care Program aims to provide access to care to 36,000 people living with breast and rare cancers, like chronic myeloid leukemia (CML), in over 70 low- and middle-income countries (LMICs) by 2025.

Geographic Reach
  • Africa
  • Americas
  • Eastern Mediterranean
  • Europe
  • South-East Asia
  • Western Pacific
See Where
Disease Area
  • Non-communicable diseases
See Disease Areas
Target Population
  • People with low incomes
  • Marginalized/indigenous people
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.4: NCDs (including mental health)
  2. 3.8: Achieve universal health coverage
SDG 9: Industry innovation and infrastructure
SDG 10: Reduced inequalities
SDG 17: Partnerships for the goals 
Partner organizations
Global NGOs

The Max Foundation